Through the use of CT and MRI, clinicians use anatomical features to assess the state of disease in patients with cancer. Unfortunately, these video methods do not quantify the level of disease or differentiate true areas of cancer from treatment related changes. One of the challenges is the lack of robust biomarkers that can be used to monitor diseases. Biomarkers are measurable indicators of disease state and can be used for prognosis purposes. Identification of biomarkers could greatly aid clinicians in diagnosis, prognosis, and treatment of pediatric brain tumors. Identifying means for testing that do not require tumor tissue would reduce the risk of permanent neurological deficit for patients with tumors that are particularly challenging to remove. One line of investigation that researchers on this project have been pursuing is the detection of cell free DNA shed from tumor cells into body fluids such as plasma and cerebrospinal fluid (CSF). All cells, including tumor cells and non-malignant cells, shed DNA, called cell-free DNA (cfDNA), into the circulatory system. Researchers recently demonstrated that levels of tumor derived DNA are significantly enriched in the CSF of individuals with brain tumors, including medulloblastoma. CSF has the potential to act as a “liquid biopsy” for children with brain tumors. Potential applications of this sort of detection include assessment of disease burden, drug resistance, and tumor evolution. Researchers have successfully completed this work for other tumor types, and will use 5 CSF samples provided by the Children’s Brain Tumor Network to extend this work to pediatric medulloblastoma.
What are the goals of this project?
Researchers will explore the usefulness of CSF samples as liquid biopsy for the diagnosis and prognosis of pediatric medulloblastoma.
What is the impact of this project?
If validated as a successful option, liquid biopsy using CSF would be a new, minimally invasive diagnostic option for patients with medulloblastoma.
Why is the CBTN request important to this project?
Researchers have carried out similar work for other tumor types and will be able to extend this work to medulloblastoma using rare samples provided by the Children’s Brain Tumor Network.
The Children's Brain Tumor Network contributed to this project by providing 5 cerebral spinal fluid samples for a pilot cohort.
Chetan Bettegowda, MD, PhD
Identify key genetic pathways that are altered in brain tumors; Developing clinical trials to selectively target these pathways; Developing targeted therapies for patients with primary and metastatic tumors of the brain and spine; Ongoing clinical protocol to develop a simple blood test that can det
Johns Hopkins Medicine
Johns Hopkins MedicineJoined on
Headquartered in Baltimore, Maryland, Johns Hopkins Medicine unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. Johns Hopkins Medicine has six academic and co
Medulloblastomas comprises the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinical feature